Use of sildenafil for the treatment of neonatal persistent pulmonary hypertension
DOI:
https://doi.org/10.33448/rsd-v13i1.44910Keywords:
Persistent fetal circulation; Sildenafil citrate; Intensive care units neonatal.Abstract
Introduction: Persistent pulmonary hypertension of the newborn is a neonatal respiratory and vascular pathology with a high mortality rate. Furthermore, its prevalence is 1 to 2 per 1000 live births, accounting for 8%-10% of neonatal deaths. The therapeutic approach involves supporting pulmonary recruitment and pharmacological vasodilation, most notably sildenafil. Methodology: The study is a narrative review of the literature that was carried out from the PUBMED database using the keywords “Persistent Pulmonary Hypertension of the Newborn” and “Sildenafil”, with the time filter in the last 30 years (1994- 2023). Discussion: Physiologically, during fetal life, the lungs remain filled with fluids, but immediately after birth, pulmonary vascular resistance decreases drastically, allowing alveolar oxygen tension and ventilation to be possible. However, in the pathogenesis of neonatal persistent pulmonary hypertension, there is an increase in pulmonary vascular resistance and remodeling of the vascular structure after birth, which potentiate this exaggerated vasoconstriction. Therefore, the standard exam for investigating the pathology is echocardiography. Sildenafil is a drug used to treat neonatal persistent pulmonary hypertension, as it enhances better blood flow and better delivery of oxygen to tissues, through its physiopharmacology aimed at vasodilation secondary to inhibition of phosphodiesterase-5. Conclusion: Neonatal persistent pulmonary hypertension is still one of the main neonatal pathologies with high morbidity and mortality in the neonatal population, due to the complexity of presentations and the variation in therapeutic responses to pharmacotherapy.
References
Abman, S. H. (2007). Recent advances in the pathogenesis and treatment of persistent pulmonary hypertension of the newborn. Neonatology, 91(4), 283–290. https://doi.org/10.1159/000101343
Ambalavanan, N., & Aschner, J. L. (2016). Management of hypoxemic respiratory failure and pulmonary hypertension in preterm infants. Journal of Perinatology: Official Journal of the California Perinatal Association, 36(Suppl 2), S20–S27. https://doi.org/10.1038/jp.2016.45
Askin, D. F. (2006). Off-label therapies for newborns: Miracles or mistakes? AWHONN Lifelines, 10(2), 160–162. https://doi.org/10.1111/j.1552-6356.2006.00029.x
Cook, L. N., & Stewart, D. L. (2005). Inhaled nitric oxide in the treatment of persistent pulmonary hypertension/hypoxic respiratory failure in neonates: an update. The Journal of the Kentucky Medical Association, 103(4), 138–147.
Cruz-Blanquel, A., Espinosa-Oropeza, A., Romo-Hernández, G., Carrillo-Alarcón, L., Ponce-Monter, H., & Ortiz, M. I. (2008). Persistent pulmonary hypertension in the newborn: therapeutic effect of sildenafil. Proceedings of the Western Pharmacology Society, 51, 73–77.
Dani, C., & Pratesi, S. (2013). Nitric oxide for the treatment of preterm infants with respiratory distress syndrome. Expert Opinion on Pharmacotherapy, 14(1), 97–103. https://doi.org/10.1517/14656566.2013.746662
Dhillon, R. (2012). The management of neonatal pulmonary hypertension. Archives of Disease in Childhood. Fetal and Neonatal Edition, 97(3), F223–F228. https://doi.org/10.1136/adc.2009.180091
Fuloria, M., & Aschner, J. L. (2017). Persistent pulmonary hypertension of the newborn. Seminars in Fetal & Neonatal Medicine, 22(4), 220–226. https://doi.org/10.1016/j.siny.2017.03.004
Gien, J., & Kinsella, J. P. (2016). Management of pulmonary hypertension in infants with congenital diaphragmatic hernia. Journal of Perinatology: Official Journal of the California Perinatal Association, 36(Suppl 2), S28–S31. https://doi.org/10.1038/jp.2016.46
Iacovidou, N., Syggelou, A., Fanos, V., & Xanthos, T. (2012). The use of sildenafil in the treatment of persistent pulmonary hypertension of the newborn: a review of the literature. Current Pharmaceutical Design, 18(21), 3034–3045. https://doi.org/10.2174/1381612811209023034
Iijima, S., Ueno, D., Baba, T., & Ohishi, A. (2018). Hypertrophic pyloric stenosis following persistent pulmonary hypertension of the newborn: a case report and literature review. BMC Pediatrics, 18(1), 290. https://doi.org/10.1186/s12887-018-1270-0
Kawaguchi, A., Isayama, T., Mori, R., Minami, H., Yang, Y., & Tamura, M. (2013). Hydralazine in infants with persistent hypoxemic respiratory failure. The Cochrane Database of Systematic Reviews, 2013(2), CD009449. https://doi.org/10.1002/14651858.CD009449.pub2
Kelly, L. E., Ohlsson, A., & Shah, P. S. (2017). Sildenafil for pulmonary hypertension in neonates. The Cochrane Database of Systematic Reviews, 8(8), CD005494. https://doi.org/10.1002/14651858.CD005494.pub4
Krishnan, U. (2010). Management of pulmonary arterial hypertension in the neonatal unit. Cardiology in Review, 18(2), 73–75. https://doi.org/10.1097/CRD.0b013e3181ce9edb
Lakshminrusimha, S., Konduri, G. G., & Steinhorn, R. H. (2016). Considerations in the management of hypoxemic respiratory failure and persistent pulmonary hypertension in term and late preterm neonates. Journal of Perinatology: Official Journal of the California Perinatal Association, 36(Suppl 2), S12–S19. https://doi.org/10.1038/jp.2016.44
Latini, G., Del Vecchio, A., De Felice, C., Verrotti, A., & Bossone, E. (2008). Persistent pulmonary hypertension of the newborn: therapeutical approach. Mini Reviews in Medicinal Chemistry, 8(14), 1507–1513. https://doi.org/10.2174/138955708786786507
Luecke, C., & McPherson, C. (2017). Treatment of Persistent Pulmonary Hypertension of the Newborn: Use of Pulmonary Vasodilators in Term Neonates. Neonatal Network: NN, 36(3), 160–168. https://doi.org/10.1891/0730-0832.36.3.160
Mandell, E., Kinsella, J. P., & Abman, S. H. (2021). Persistent pulmonary hypertension of the newborn. Pediatric Pulmonology, 56(3), 661–669. https://doi.org/10.1002/ppul.25073
Martinho, S., Adão, R., Leite-Moreira, A. F., & Brás-Silva, C. (2020). Persistent Pulmonary Hypertension of the Newborn: Pathophysiological Mechanisms and Novel Therapeutic Approaches. Frontiers in Pediatrics, 8, 342. https://doi.org/10.3389/fped.2020.00342
Oishi, P., Datar, S. A., & Fineman, J. R. (2011). Advances in the management of pediatric pulmonary hypertension. Respiratory Care, 56(9), 1314–1340. https://doi.org/10.4187/respcare.01297
Panigrahy, N., Chirla, D. K., Shetty, R., Shaikh, F. A. R., Kumar, P. P., Madappa, R., Lingan, A., & Lakshminrusimha, S. (2020). Thiamine-Responsive Acute Pulmonary Hypertension of Early Infancy (TRAPHEI)-A Case Series and Clinical Review. Children (Basel, Switzerland), 7(11), 199. https://doi.org/10.3390/children7110199
Pedersen, J., Hedegaard, E. R., Simonsen, U., Krüger, M., Infanger, M., & Grimm, D. (2018). Current and Future Treatments for Persistent Pulmonary Hypertension in the Newborn. Basic & Clinical Pharmacology & Toxicology, 123(4), 392–406. https://doi.org/10.1111/bcpt.13051
Perez, K. M., & Laughon, M. (2015). Sildenafil in Term and Premature Infants: A Systematic Review. Clinical Therapeutics, 37(11), 2598–2607.e1. https://doi.org/10.1016/j.clinthera.2015.07.019
Rother, E. T. (2007). Systematic literature review X narrative review. Acta Paulista de Enfermagem, 20(2), v–vi. https://doi.org/10.1590/s0103-21002007000200001
Samiee-Zafarghandy, S., Smith, P. B., & van den Anker, J. N. (2014). Safety of sildenafil in infants. Pediatric Critical Care Medicine: A Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies, 15(4), 362–368. https://doi.org/10.1097/PCC.0000000000000077
Sanchez Luna, M., Franco, M. L., & Bernardo, B. (2012). Therapeutic strategies in pulmonary hypertension of the newborn: where are we now? Current Medicinal Chemistry, 19(27), 4640–4653. https://doi.org/10.2174/092986712803306475
Shah, P. S., & Ohlsson, A. (2007). Sildenafil for pulmonary hypertension in neonates. The Cochrane Database of Systematic Reviews, (3), CD005494. https://doi.org/10.1002/14651858.CD005494.pub2
Simonca, L., & Tulloh, R. (2017). Sildenafil in Infants and Children. Children (Basel, Switzerland), 4(7), 60. https://doi.org/10.3390/children4070060
Snyder, H. (2019). Literature Review as a Research methodology: an Overview and Guidelines. Journal of Business Research, 104(1), 333–339. Science direct. https://doi.org/10.1016/j.jbusres.2019.07.039
Spillers, J. (2010). PPHN: is sildenafil the new nitric? A review of the literature. Advances in Neonatal Care: Official Journal of the National Association of Neonatal Nurses, 10(2), 69–74. https://doi.org/10.1097/ANC.0b013e3181d5c501
Steinhorn, R. H. (2016). Advances in Neonatal Pulmonary Hypertension. Neonatology, 109(4), 334–344. https://doi.org/10.1159/000444895
Storme, L., Aubry, E., Rakza, T., Houeijeh, A., Debarge, V., Tourneux, P., Deruelle, P., Pennaforte, T., & French Congenital Diaphragmatic Hernia Study Group (2013). Pathophysiology of persistent pulmonary hypertension of the newborn: impact of the perinatal environment. Archives of Cardiovascular Diseases, 106(3), 169–177. https://doi.org/10.1016/j.acvd.2012.12.005
Sun, H., Stockbridge, N., Ariagno, R. L., Murphy, D., Nelson, R. M., & Rodriguez, W. (2016). Reliable and developmentally appropriate study endpoints are needed to achieve drug development for treatment of pediatric pulmonary arterial hypertension. Journal of Perinatology: Official Journal of the California Perinatal Association, 36(12), 1029–1033. https://doi.org/10.1038/jp.2016.103
Verklan M. T. (2006). Persistent pulmonary hypertension of the newborn: not a honeymoon anymore. The Journal of perinatal & neonatal nursing, 20(1), 108–112. https://doi.org/10.1097/00005237-200601000-00031
Yaseen, H., Darwich, M., & Hamdy, H. (2012). Is sildenafil an effective therapy in the management of persistent pulmonary hypertension? Journal of Clinical Neonatology, 1(4), 171–175. https://doi.org/10.4103/2249-4847.105958
Zhang, W., Wu, Y. E., Yang, X. Y., Shi, J., van den Anker, J., Song, L. L., & Zhao, W. (2020). Oral drugs used to treat persistent pulmonary hypertension of the newborn. Expert Review of Clinical Pharmacology, 13(12), 1295–1308. https://doi.org/10.1080/17512433.2020.1850257
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 José de Ribamar Barroso Jucá Neto; Ângela Rocha Mapurunga; Angelica Gomes Belchior; Felipe Rabelo Costa; Vitor Teixeira Boscov
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
